Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup
Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a hold rating in a research note ...
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...
Benzinga.com3d
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
2 Top Growth Stocks to Buy on the Dip
Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Yahoo Finance3d
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
The latest research advances demonstrate the potential of Regeneron’s diverse pipeline, which aims to address unmet needs in ten types of blood cancers and disorders. These innovative and ...
Regeneron initiated with a Neutral at Citi
Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...